Data from the Phase II trial saw three of the seven patients dosed with CAN-2409 surviving for more than 35 months.

Ferring Pharma’s Adstiladrin is a non-replicating (cannot multiply in human cells) adenoviral vector-based gene therapy. Its safety and efficacy was evaluated in a multi-centre clinical study of ...